Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers

Conclusions
Based on the RADAR/JAPAN study, with short-term changes in risk markers, atrasentan is expected to decrease renal risk without increased risk of heart failure. Within this population albuminuria responders appear to contribute to the predicted improvements, whereas non-responders showed no benefit. The ongoing hard outcome trial (SONAR) in type 2 diabetic patients with >30% albuminuria reduction to atrasentan will allow us to assess the validity of these predictions.

Source: European Journal of Preventive Cardiology - April 3, 2016 Category: Cardiology Authors: Schievink, B., de Zeeuw, D., Smink, P. A., Andress, D., Brennan, J. J., Coll, B., Correa-Rotter, R., Hou, F. F., Kohan, D., Kitzman, D. W., Makino, H., Parving, H.-H., Perkovic, V., Remuzzi, G., Tobe, S., Toto, R., Hoekman, J., Lambers Heerspink, H. J. Tags: Original scientific papers Source Type: research